First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
dc.contributor.author | Van Cutsem, E. | |
dc.contributor.author | Danielewicz, I. | |
dc.contributor.author | Saunders, Mark P | |
dc.contributor.author | Pfeiffer, P. | |
dc.contributor.author | Argilés, G. | |
dc.contributor.author | Borg, C. | |
dc.contributor.author | Glynne-Jones, R. | |
dc.contributor.author | Punt, C. J. A. | |
dc.contributor.author | Van de Wouw, A. J. | |
dc.contributor.author | Fedyanin, M. | |
dc.contributor.author | Stroyakovskiy, D. | |
dc.contributor.author | Kroening, H. | |
dc.contributor.author | Garcia-Alfonso, P. | |
dc.contributor.author | Wasan, H. | |
dc.contributor.author | Falcone, A. | |
dc.contributor.author | Fougeray, R. | |
dc.contributor.author | Egorov, A. | |
dc.contributor.author | Amellal, N. | |
dc.contributor.author | Moiseyenko, V. | |
dc.date.accessioned | 2022-05-26T08:35:10Z | |
dc.date.available | 2022-05-26T08:35:10Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Vol. 126, British Journal of Cancer. Springer Science and Business Media LLC; 2022. p. 1548–54. | en |
dc.identifier.pmid | 35440667 | en |
dc.identifier.doi | 10.1038/s41416-022-01737-2 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625264 | |
dc.description.abstract | Background: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here, we present the final overall survival (OS) results. Methods: TASCO1 was an open-label, non-comparative phase II trial. Patients (n = 153) were randomised 1:1 to TT-B (trifluridine/tipiracil 35 mg/m2 orally twice daily on days 1-5 and 8-12, and bevacizumab intravenously 5 mg/kg on days 1 and 15 of each 28-day cycle) or capecitabine plus bevacizumab (C-B; capecitabine, 1250 mg/m2 orally twice daily on days 1-14 and bevacizumab 7.5 mg/kg intravenously on day 1 of each 21-day cycle). Final OS was analysed when all patients had either died or withdrawn from the study. Adjusted multivariate regression was used to investigate the effects of pre-specified variables on OS. Results: At 1 September 2020, median OS was 22.3 months (95% CI: 18.0-23.7) with TT-B and 17.7 months (95% CI: 12.6-19.8) with C-B (adjusted HR 0.78; 95% CI: 0.55-1.10). No variables negatively affected OS with TT-B. Safety results were consistent with prior findings. Conclusions: TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1038/s41416-022-01737-2 | en |
dc.title | First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | en |
dc.type | Article | en |
dc.contributor.department | University Hospitals Leuven and KU Leuven, Leuven, Belgium | en |
dc.identifier.journal | British Journal of Cancer | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-06-29T09:07:05Z |